AbbVie Inc $ 103.92 -0.04 (-0.03%)
ABBV News and Headlines - AbbVie Inc
The Dividend Stocks screener at GuruFocus finds 616 dividend stocks held by the gurus as of the writing of this article. Another 19 are listed as over-the-counter stocks.
The output from the screener can be sorted in several ways. I've sorted by the largest number of gurus buys in the previous quarter. According to this search, Wells Fargo & Co (WFC), Pfizer Inc (PFE) and AbbVie Inc (ABBV) are the most popular dividend stocks among gurus. In other words, these are the three companies with good dividends that had the highest number of guru buys in the quarter ended
Jim Simons (Trades, Portfolio), founder of Renaissance Technologies LLC, has released his firm's portfolio for the third quarter. The guru cut down dozens of holdings, with the largest impacts coming from Tesla Inc. (TSLA), Bristol-Myers Squibb Co. (BMY), Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Zoom Video Communications Inc. (ZM).
Renaissance Technologies is a quantitative investment management company that trades in global financial markets. The company is dedicated to adhering to mathematical and statistical methods. Investments are made using a computer algorithm and trades are conducted for Simons by his firm.
At the end
Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway (BRK.A) (BRK.B) filed its 13F report for the third quarter on Monday this week. The announcement revealed that the Oracle of Omaha made some exciting changes to his portfolio during the reported period, including several investments in pharmaceutical companies.
Before we continue, investors should note that this filing only provides a snapshot of the portfolio at one point in time. It details the equity positions in the portfolio as of the end of September 2020. It does not include any cash or credit holdings or any changes made after the quarter
With more than $140 billion to spend on stocks, the renowned guru and his two portfolio managers, Ted Weschler and Todd Combs, entered six new positions during the quarter, which were mainly biotech companies. In addition to the previously revealed stake in Snowflake Inc. (SNOW), Berkshire invested in AbbVie Inc. (ABBV), Merck & Co. Inc. (MRK), Bristol-Myers Squibb Co. (BMY), T-Mobile US Inc. (TMUS) and Pfizer Inc. (PFE).
As previously disclosed in July and
Shares of AbbVie Inc.(ABBV) have soared nearly 18% less than a week after the company reported outstanding results for the third quarter and upped its guidance for the full year.
The Chicago-area pharmaceutical titan had quarterly earnings of $2.83 per share, beating the Zacks consensus estimate of $2.75. Over the last four quarters, the company has topped consensus earnings estimates four times. Revenue for the quarter also surpassed estimates, coming in at nearly $14 billion. The company also boosted its guidance for the year by a few cents to between $10.47 and $10.49.
AbbVie is embracing a philosophy often used
AbbVie Inc. (ABBV), a name I have felt is undervalued for some time, reported third-quarter earnings results Friday morning that easily topped Wall Street's estimates. The company also gave yet another double-digit dividend increase.
With all the positives going for the company, AbbVie still looks incredibly undervalued. This is why, in combination with the company's pipeline and high yield, I feel that AbbVie should be at the top of the list for investors looking for exposure to the health care industry.
AbbVie's adjusted earnings per share of $2.83 was an increase of 50 cents, or
U.S. stocks were in the red on Friday morning. The Dow fell 1.58%to 26,238, the S&P 500 index lost 1.83% to 3,249 and the Nasdaq Composite Index was down 2.51%, to 10,904.
• Mohawk Industries Inc (MHK) +11.9%
• Abbvie Inc (ABBV) +5.2%
• Resmed Inc (RMD) +6.7%
• Under Armour Inc (UA) +1.3%
• MGM Resorts International (MGM) -7.1%
• Ralph Lauren Corp (RL) -5.8%
• Cabot Oil & Gas Corp (COG) -4%
• ServiceNow Inc (NOW) -4.5%
• Weyerhaeuser Co (WY) -5.2%
The main European stock markets traded in the
Managed by Jason Kritzer and Samantha Pandolfi, the fund, which is part of Boston-based Eaton Vance, invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.
Although the fund added six new holdings to the portfolio during the three months ended Aug. 31, its most notable trades included an addition to its AbbVie
Management's Discussion of Fund Performance1
Economic and Market Conditions
The 12-month period that began September 1, 2019 (the period), included some of the best and worst equity performances in over a decade.
The period began with global equities rallying in the closing months of 2019, supported by interest rate reductions by many central banks worldwide. The previous July, the U.S. Federal Reserve (the Fed) had cut rates for the first time in over a decade, followed by two additional rate cuts in the first two months of the period. By the end of the third quarter of 2019, interest rates
Buying shares of companies trading well above off their average valuation and dividend yield can mean adding a stock with significant growth potential.
One of my favorite low multiple, high-yield stocks remains AbbVie Inc. (ABBV). The company's dividend track record and valuation show why this health care company should be consider by dividend growth and value investors alike.
Company background and historical performance
Spun off from parent company Abbott Laboratories (ABBV) in 2013, AbbVie is one of the largest pharmaceutical companies in the world. The company's products address illnesses and diseases such as rheumatoid arthritis, HIV, blood cancers, Crohn's disease
As of Oct. 2, the following stocks seem to be undervalued by the market, as their price-earnings ratios are below 20 and their price-earnings to growth (PEG) ratios stand below 1. Furthermore, these stocks have received positive recommendation ratings from sell-side analysts on Wall Street.
The first company that meets the criteria is AbbVie Inc (ABBV), a North Chicago, Illinois-based drug major.
Shares closed at a price of $86.12 each on Friday for a market capitalization of $151.99 billion.
The price-earnings ratio of 18.32 is more compelling than the industry median of 24.4, while the PEG ratio
Here's a switch: Analysts are predicting sales for a Sanofi (SNY) blockbuster drug that exceed the company's forecast.
Jefferies analysts wrote Dupixent revenue is likely to peak at $12.5 billion, according to an article in FiercePharma. That's about 8% higher than Sanofi CEO Paul Hudson has set for the medication.
Dupixent is the first biologic medication approved by the Food and Drug Administration for adults and children aged six years and up with moderate to severe atopic dermatitis for whom topical treatments have not worked or are not advised.
Atopic is the most common type of eczema, affecting more than
Shares of Pfizer (PFE) have declined almost 7% since I last looked at the company in depth. Despite this weakness, I believe that the company has strong prospects for growth. The stock continues to offer a dividend yield that is superior to its long-term average while trading with a very low price-earnings multiple.
This article will examine why I think Pfizer remains a strong buy for investors looking for exposure to the health care sector.
Pfizer reported second quarter earnings results on July 28. The company's revenue fell 11% year-over-year to $11.8 billion, but managed to
Swiss food and beverage giant Nestle (OTCPK:NSRGY) is paying more than $2 billion for Aimmune Therapeutics, Inc. (AIMT) to bag the California-based company's drug Palforzia, a peanut allergy medication that was approved by the Food and Drug Administration earlier this year.
Nestle already owned more than 25% of Aimmune. The all-cash deal values the company at $2.6 billion. At $34.50 per share, the price amounts to a 174% premium on Aimmune's closing price as of Friday, as Nestlé said in the news release. The purchase is expected to close in the fourth quarter of 2020.
Adding Aimmune will
The last three categories of drugs being studied for Alzheimer's are metabolic approaches, stem cell and gene therapies and alternative medicines. The first four were reviewed previosly, with the most popular approach being aimed at the physical changes (amyloid/tau) in the brains of Alzheimer's patients.
Diabetes is a metabolic disease, so some scientists speculate that Alzheimer's is really the third type of diabetes, according to FierceBiotech. That's because some forms of Alzheimer's seem to be related to insulin resistance, the main problem in type 2 diabetes. Research has shown that people with this form of diabetes have a greater risk
With the long-term goal of capital preservation, above-average returns and low correlation to the market, the guru's New York-based firm specializes in event-driven arbitrage strategies, including merger arbitrage, bankruptcy reorganizations and distressed credit.
Sticking to these criteria, the investor revealed he established four new positions during the quarter, exited seven stocks and added to or reduced a number of other holdings. Notable transactions included the addition of TD Ameritrade Holding Corp. (AMTD) to the portfolio, as well as significant
David Abrams (Trades, Portfolio), founder of Abrams Capital Management, disclosed this week that he sold out of Suburban Propane Partners LP (SPH), boosted his position in Kinder Morgan Inc. (KMI) and eliminated over 90% of his stake in Pacific Drilling SA (PACD) during the second quarter.
Managing a portfolio of 22 stocks, the pupil of Baupost Group manager Seth Klarman (Trades, Portfolio) seeks companies in which the CEO has a significant stake or where the CEO's salary is primarily stock-based. Abrams employs a value approach to investing.
The New York-based firm, which has been operating for a century, is an investment partnership that is owned and operated by its four managing directors, William H. Browne, John D. Spears, Thomas H. Shrager and Robert Q. Wyckoff Jr. Deriving its investment approach from the work of Benjamin Graham, the firm oversees around $4.5 billion in assets through four unique mutual funds. Each of the portfolios is managed according to the same value principles with an emphasis on seeking undervalued stocks.
According to the GuruFocus All-in-One Screener, a Premium feature, the stocks of the following guru-owned health care companies have outperformed the S&P 500 Index over the past 12 months through July 10.
UnitedHealth Group Inc. (UNH) has a market cap of $287.94 billion. It has outperformed the S&P 500 by 7.42% over the past year.
Shares are trading with a price-earnings ratio of 7.08. As of Friday, the share price was 61.74% above the 52-week low and 3.87% below the 52-week high.
The company has a GuruFocus profitability rating of 8 out of 10. The return on
Dividend investors may be interested in the following stocks, as they are currently significantly outperforming the S&P 500 index in terms of higher dividend yields. The benchmark for the U.S. market grants an average yield of 1.78% as of Aug. 7.
Furthermore, Wall Street sell-side analysts have issued positive recommendation ratings for these stocks, suggesting that their share prices are expected to trade higher.
The first company that makes the cut is AbbVie Inc (ABBV), a U.S. drug major based in North Chicago, Illinois.
Based on Thursday's closing price of $92.57 per share, AbbVie Inc grants a